Clinical Trial Update: Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Antineoplaston Therapy for Stage III or Stage IV ovarian cancer was terminated. The sponsor was Burzynski Research Institute.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Antineoplaston therapy

Snippet

Sponsor: Burzynski Research Institute | Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer | Phase 2 | Status: TERMINATED